Skip to main content
رجوع
PCRX logo

Pacira BioSciences, Inc.

جودة البيانات: 100%
PCRX
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 22.65
▲ KWD 0.54 (2.44%)
القيمة السوقية: 974.43M
نطاق اليوم
KWD 22.12 KWD 22.81
نطاق 52 أسبوعًا
KWD 18.80 KWD 27.64
حجم التداول
517,035
متوسط 50 يوم / 200 يوم
KWD 21.87 / KWD 23.66
الإغلاق السابق
KWD 22.11

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 138.5 0.4
P/B 1.4 2.9
ROE % 1.0 3.8
Net Margin % 1.0 3.9
Rev Growth 5Y % 7.6 10.0
D/E 0.7 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 4.950
KWD 4.869 – KWD 5.056
940 M 2
FY2029 KWD 4.600
KWD 4.525 – KWD 4.699
920 M 2
FY2028 KWD 5.180
KWD 5.095 – KWD 5.291
960 M 3

النقاط الرئيسية

Revenue grew 7.62% annually over 5 years — modest growth
ROE of 0.96% is below average
Generating 136.66M in free cash flow
P/E of 138.53 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.99%
Cash machine — converts 1942.86% of earnings into free cash flow

النمو

Revenue Growth (5Y)
7.62%
Revenue (1Y)3.63%
Earnings (1Y)N/A
FCF Growth (3Y)-1.02%

الجودة

Return on Equity
0.96%
ROIC1.84%
Net Margin0.97%
Op. Margin3.87%

الأمان

Debt / Equity
0.66
Current Ratio4.54
Interest Coverage1.61

التقييم

P/E Ratio
138.53
P/B Ratio1.41
EV/EBITDA45.20
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3.63% Revenue Growth (3Y) 3.74%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -59.05%
Revenue Growth (5Y) 7.62% Earnings Growth (5Y) -36.02%
Profitability
Revenue (TTM) 726.41M Net Income (TTM) 7.03M
ROE 0.96% ROA 0.56%
Gross Margin 71.50% Operating Margin 3.87%
Net Margin 0.97% Free Cash Flow (TTM) 136.66M
ROIC 1.84% FCF Growth (3Y) -1.02%
Safety
Debt / Equity 0.66 Current Ratio 4.54
Interest Coverage 1.61 Dividend Yield 0.00%
Valuation
P/E Ratio 138.53 P/B Ratio 1.41
P/S Ratio 1.34 PEG Ratio -1.53
EV/EBITDA 45.20 Dividend Yield 0.00%
Market Cap 974.43M Enterprise Value 1.27B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 726.41M 700.97M 674.98M 666.82M 541.53M
Net Income 7.03M -99.56M 41.96M 15.91M 41.98M
EPS (Diluted) 0.16 -2.15 0.89 0.34 0.92
Gross Profit 519.37M 530.54M 490.31M 467.53M 401.28M
Operating Income 28.10M -73.37M 87.68M 60.02M 89.92M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.26B 1.55B 1.57B 1.68B 2.08B
Total Liabilities 571.81M 775.17M 704.26M 906.19M 1.34B
Shareholders' Equity 693.11M 778.35M 870.13M 775.01M 730.41M
Total Debt 454.38M 638.85M 586.04M 763.39M 1.13B
Cash & Equivalents 158.55M 276.77M 153.30M 104.14M 585.58M
Current Assets 547.97M 745.13M 509.99M 498.33M 866.05M
Current Liabilities 120.59M 309.92M 97.38M 147.77M 521.12M